NY-ESO-1 engineered T cells

NY-ESO-1 engineered T cells are autologous T lymphocytes that have been genetically modified to express a high-affinity T-cell receptor (TCR) specific for the NY-ESO-1 antigen, a cancer-testis antigen frequently expressed in various advanced solid and hematological tumors but rarely in normal tissues. These engineered T cells are produced by collecting a patient's own T cells, retrovirally transducing them to express the NY-ESO-1 reactive TCR, expanding them ex vivo, and then reinfusing them into the patient following lymphodepleting chemotherapy[1][2][7]. By targeting NY-ESO-1, these cells mediate direct cytolytic activity against tumor cells expressing the antigen, leading to tumor regression and prolonged survival in several cancers, including synovial sarcoma, melanoma, multiple myeloma, and neuroblastoma. Response rates in clinical trials include objective responses in 55–61% of melanoma and synovial sarcoma patients, and ~80% clinical response in multiple myeloma[2][4][6][7]. Early-phase trials have demonstrated manageable safety profiles with little cytokine release syndrome[2]. NY-ESO-1 TCR-T therapies remain investigational but are being assessed in multiple ongoing trials for a variety of solid and hematologic malignancies[4][6][7][9].

Other names

NY-ESO-1 TCR-T cellsNY-ESO1 TCR-T cellsNY-ESO 1 TCR-T cellsNY-ESO-1-specific TCR-T cellsNY-ESO1-specific TCR-T cellsNY-ESO 1-specific TCR-T cellsNY-ESO^c259^ TCR-T cells